NCT07113743
Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease
Enrolling by Invitation
PHASE1Ages 3–60InterventionalTreatmentNational Institute of Allergy and Infectious Diseases (NIAID)Government-funded
~10 participants
Updated 2026-07-24 on ClinicalTrials.gov
What's tested:BusulfanTocilizumabEltrombopagSirolimuspCCLChimGp91lentiviral vector containing the human gp91 phox (CYBB) gene
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Safety
Measured over Throughout the study
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesMaryland1
Study leadership
- Elizabeth M Kang, M.D. · PRINCIPAL_INVESTIGATOR · National Institute of Allergy and Infectious Diseases (NIAID)
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Must have confirmed molecular diagnosis of X-linked CGD confirmed by deoxyribonucleic acid (DNA) sequencing and supported by laboratory evidence for absent or reduction \>90% of the biochemical activity of the NADPH-oxidase.
At least 1 prior ongoing or refractory severe infection and/or inflammatory complications requiring hospitalization despite conventional therapy.
No 10/10 HLA-matched donor available after initial search of National Marrow Donor Program (NMDP) registries within the last year.
Must weigh at least 15 kg.
Male or female, and must be at least 3 years of age but no older than 60.
Parent/guardian must be willing to sign and date informed consent form for child and where appropriate, child may sign assent.
Stated willingness to comply with all study procedures and availability for the duration of the study.
Ability to take oral medication and be willing to adhere to the prophylactic regimen.
Apheresis of patients for the hematopoietic stem cells collected as a part of this protocol will be performed according to the Standard of Care apheresis practices established in the NIH CC Department of Transfusion Medicine for such procedures.
For apheresis, pediatric patients:
Must weigh at least 15 kg body weight;
Preserved renal function (creatinine \<=2.5 mg/dL; \<=3+ proteinuria); preserved hepatic function (bilirubin \<=2.0 mg/dl);
Must be negative for co-infection with human immunodeficiency virus (HIV) or hepatitis B virus (HBsAg positive) or hepatitis C virus (HCV ribonucleic acid (RNA) positive), adenovirus, parvovirus B 19 or toxoplasmosis or mycobacterial infection (prior or current).
For females of reproductive potential, must agree to use of 2 highly effective contraception throughout study participation and for at least 3 months after the study.
For females:
Condoms, male or female, with or without a spermicide;
Diaphragm or cervical cap with spermicide;
Intrauterine device;
Contraceptive pills or patch, Norplant, Depo-Provera, or other FDA- approved contraceptive method;
For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner.
Agreement to adhere to Lifestyle Considerations throughout study duration.
Ability of subject (Patient/Legal Guardian) to understand and the willingness to sign a written informed consent document.
For the Natural History Protocol (05-I-0213): All patients must be willing to allow storage of blood samples for future studies.
Must provide a durable power of attorney (DPA) for health care decisions to an appropriate adult relative or guardian in accordance to NIH-200 "NIH Advance Directive for Health Care and Medical Research Participation."
Exclusion
Patient/Parent/Guardian unable or unwilling to comply with the protocol requirements.
Contraindication for leukapheresis (anemia Hb \<8 g/dl, cardiovascular instability, severe coagulopathy).
Patients who are unable to lie prone during the bone marrow harvesting procedure (in the case of bone marrow harvest, contraindication to general anesthesia).
Have a 10/10 HLA identical (A,B,C,DR,DQ) family or unrelated adult donor unless there is deemed to be an unacceptable risk associated with an allogeneic procedure.
Tested positive (definitive) for the presence of multiple types (2 or more) of anti-platelet antibodies.
Altered organ function as outlined below observed within 8 weeks of entering this trial.
Chemistry Lab abnormalities: Serum sodium \>= 156 mmol/L or \<= 129 mmol/L, potassium \>= 6.1 mmol/L or \<= 2.9 mmol/L, calcium \>= 3.2 mmol/L or \< 1.74 mmol/L , magnesium \>= 1.24 mmol/L or \< 0.39 mmol/L, phosphate \>= 5.1 mmol/L or \< 1.9 mmol/L.
Serum transaminases \> 5X the upper limit of normal (ULN).
General
Expected survival \< 6 months.
Major congenital anomaly.
Known allergic reactions to components of busulfan or dimethyl sulfoxide (DMSO) or contraindication for administration of conditioning medication.
Evidence of active malignant disease.
Treatment with another investigational drug or other intervention within 6 months.
Unable to undergo apheresis as per the NIH CC Department of Transfusion Medicine Standard of Care apheresis procedures.
Administration of gamma-interferon within 30 days before the infusion of transduced, autologous CD34+ cells.
Any other condition that, in the opinion of the Investigator, may compromise the safety or compliance of the patient or would preclude the patient from successful study completion.
What this trial measures
- SafetyThroughout the study
1\) The primary safety objective of this procedure will be assessed by recording the incidence of adverse events. a) Record clinical adverse events and clinically significant laboratory abnormalities. b) Evaluate overall incidence of adverse events for the study as a whole. c) Monitor the incidence of serious adverse events.
- Efficacy6 months and 1 year
The primary efficacy objective of this study will be determined by measuring the percentage of subjects who have \>= 10% oxidase positive granulocytes by DHR flow cytometry at month 6 and 12 after transplant.